Lithium is associated with an increased risk for thyroid dysfunction and chronic kidney disease (CKD) in patients with ...

Lithium is associated with an increased risk for thyroid dysfunction and chronic kidney disease (CKD) in patients with ...

DelveInsight’s, “Schizophrenia Pipeline Insight” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Schizophrenia pipeline landscape. It covers the Schizophrenia ...

With an understanding of the healthcare ecosystem, Sayer's expertise in strategy, transformation and payer negotiations is expected to be pivotal in progressing the company’s programmes, particularly ...

Lyndra Therapeutics®, a clinical-stage biopharmaceutical company pioneering long-acting oral therapies, today announced the Board of Directors has appointed Adam Sayer as President and Chief Executive ...

His deep understanding of the healthcare ecosystem and track record of operational excellence will be instrumental in advancing Lyndra’s pivotal program for oral weekly risperidone (LYN-005 ...

Lyndra’s long-acting oral therapies, including lead investigational product oral weekly risperidone (LYN-005), are designed to deliver medication for a week or longer with a single oral dose.

Given the favorable results, Lyndra elected to stop the study early. The biotech’s long-acting risperidone candidate is slated to enter a phase 3 safety trial in the first half of 2025.

Lyndra’s long-acting oral therapies, including lead investigational product oral weekly risperidone (LYN-005), are designed to deliver medication for a week or longer with a single oral dose.